AGATA GABRYELSKA ET AL: "IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), XP055724152, DOI: 10.3389/fimmu.2019.00692 (B1)

ALLINNE JEANNE ET AL: "IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 6, 25 September 2019 (2019-09-25), pages 1624, XP085935196, ISSN: 0091-6749, [retrieved on 20190925], DOI: 10.1016/J.JACI.2019.08.039 (B1)

ANONYMOUS: "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations - Full Text View - ClinicalTrials.gov", 22 December 2021 (2021-12-22), XP055982456, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT05166889> [retrieved on 20221117] (B1)

ANONYMOUS: "Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov", 12 October 2020 (2020-10-12), XP055787787, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03546907> [retrieved on 20210319] (B1)

WO-A1-2021/228760 (B1)

SCOTT I. ET AL: "Proof of Mechanism for Anti-Interleukin-33 Antibody Tozorakimab in a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease", B21. BASIC, CLINICAL, AND TRANSLATIONAL COPD STUDIES: THE ONGOING HUNT FOR UNDERLYING MECHANISMS AND THERAPEUTIC TARGETS, 1 May 2022 (2022-05-01), pages A2397 - A2397, XP055982451, Retrieved from the Internet <URL:http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A2397> DOI: 10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A2397 (B1)

WO-A1-2016/156440 (B1)

WO-A1-2021/089563 (B1)

WO-A1-2021/183849 (B1)

CHUAN QIU ET AL: "Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice", CANCER RESEARCH, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 138, no. 1, 13 December 2012 (2012-12-13), pages 76 - 82, XP071276272, ISSN: 0019-2805, DOI: 10.1111/IMM.12020 (B1)